Prospective Observational Pilot Study to Evaluate the Effect of Sevoflurane in ARDS patients

Mizobuchi Satoshi0 个研究点目标入组 25 人开始时间: 2022年5月1日最近更新: 2023年10月17日

试验速览

暂无简介。

•1. patients admitted to ICU
•2. patients aged 20 years or older at the time of consent
•3. more than 48 hours but less than 1 week after onset of ARDS
•4. patients on ventilator who are sedated with propofol
•5. Patients that an average of one hour of spontaneous respiratory volume was 10 ml/kg (predicted
•body weight*) or more even for more than 1 hour even using a maximum dose of 3 mg/kg/h of propof
•ol.Predicted weight: Male: 50.0 + 0.91 x (height - 152.4 (cm)), Female: 45.5 + 0.91 x (height - 152.4 (c
•6. Patients who will be on a ventilator for more than 48 hours after enrollment in the study.
•7. Patients who have given written explanation of this study to the patient or the substitute, and have
•obtained written consent from the patient or the substitute.

•1. Patients with jaundice or unexplained fever after previous use of halogenated anesthetics
•2. patients with a history of hypersensitivity to anycomponent of sevoflurane
•3. patients with clinical evaluation of intracranial hypertension or possible intracranial hypertension
•4. patients with a history or family history of malignant hyperthermia
•5. patients with muscular dystrophy, central core disease, multimini core disease, King Denborough s
•6. patients with a history of epilepsy
•7. patients with trauma to the trunk
•8. patients with hepatic insufficiency (serum total bilirubin > 2 mg/dL within 2 days of enrollment)
•9. Patients with renal failure (serum creatinine > 2mg/dL within 2 days of enrollment)
•10. Patients with anticipated anaconda S obstruction due to excessive secretions
•11. patients with known pregnancy
•12. patients with acute SARS-Cov-2 infection
•13. patients who are judged as inappropriate by the person in charge of this study

发起方

Mizobuchi Satoshi